Human Anti-CCR4 Minibody Gene Transfer for the Treatment of Cutaneous T-Cell Lymphoma

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Han, Thomas ^a   Abdel Motal, Ussama M ^a   Chang, De Kuan ^a   Sui, Jianhua ^a   Muvaffak, Asli ^a   Campbell, James ^b   Zhu, Quan ^a   Kupper, Thomas S ^b   Marasco, Wayne A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD16A ANTIGEN; CD56 ANTIGEN; CHEMOKINE RECEPTOR CCR4; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY H1567; PARVOVIRUS VECTOR; SINGLE CHAIN VARIABLE FRAGMENT FC FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MOUSE; NATURAL KILLER CELL; NEUTROPHIL COUNT; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SURVIVAL; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; DEPENDOVIRUS; DNA PRIMERS; FLOW CYTOMETRY; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, T-CELL, CUTANEOUS; MICE; MICE, SCID; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CCR4; SINGLE-CHAIN ANTIBODIES; TRANSDUCTION, GENETIC;

MURINAE; MUS;

EID: 84866006613     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044455     Document Type: Article

References (50)

1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105: 3768-3785.
2. Girardi M, Heald PW, Wilson LD, (2004) The pathogenesis of mycosis fungoides. N Engl J Med 350: 1978-1988.
3. Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, et al. (2005) Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 115: 798-812.
4. Yamanaka K, Yawalkar N, Jones DA, Hurwitz D, Ferenczi K, et al. (2005) Decreased T-cell receptor excision circles in cutaneous T-cell lymphoma. Clin Cancer Res 11: 5748-5755.
5. Yawalkar N, Ferenczi K, Jones DA, Yamanaka K, Suh KY, et al. (2003) Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 102: 4059-4066.
6. Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, et al. (2012) Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients. Sci Transl Med 4: 117ra117.
7. Campbell JJ, Clark RA, Watanabe R, Kupper TS, (2010) Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 116: 767-771.
8. Wu CS, Wang ST, Liao CY, Wu MT, (2008) Differential CCR4 expression and function in cutaneous T-cell lymphoma cell lines. Kaohsiung J Med Sci 24: 577-590.
9. Wu XS, Lonsdorf AS, Hwang ST, (2009) Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. J Invest Dermatol 129: 1115-1119.
10. Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Lenz J, Speuser P, et al. (2005) Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol 152: 258-264.
11. Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS, (2002) Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 119: 1405-1410.
12. Vermeer MH, Dukers DF, ten Berge RL, Bloemena E, Wu L, et al. (2002) Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease. Mod Pathol 15: 838-844.
13. Baekkevold ES, Wurbel MA, Kivisakk P, Wain CM, Power CA, et al. (2005) A role for CCR4 in development of mature circulating cutaneous T helper memory cell populations. J Exp Med 201: 1045-1051.
14. Kunkel EJ, Boisvert J, Murphy K, Vierra MA, Genovese MC, et al. (2002) Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am J Pathol 160: 347-355.
15. Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, et al. (1999) The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 400: 776-780.
16. Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, et al. (2009) Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res 69: 5996-6004.
17. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
18. Watanabe Y, Katou F, Ohtani H, Nakayama T, Yoshie O, et al. (2010) Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109: 744-752.
19. Ferris RL, Jaffee EM, Ferrone S, (2010) Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 28: 4390-4399.
20. Deckert PM, (2009) Current constructs and targets in clinical development for antibody-based cancer therapy. Curr Drug Targets 10: 158-175.
21. Sui J, Aird DR, Tamin A, Murakami A, Yan M, et al. (2008) Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog 4: e1000197.
22. Selvaraj P, Fifadara N, Nagarajan S, Cimino A, Wang G, (2004) Functional regulation of human neutrophil Fc gamma receptors. Immunol Res 29: 219-230.
23. Siders WM, Shields J, Garron C, Hu Y, Boutin P, et al. (2010) Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma 51: 1293-1304.
24. Fleming TJ, O'HUigin C, Malek TR, (1993) Characterization of two novel Ly-6 genes. Protein sequence and potential structural similarity to alpha-bungarotoxin and other neurotoxins. J Immunol 150: 5379-5390.
25. Fleming TJ, Fleming ML, Malek TR, (1993) Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol 151: 2399-2408.
26. Berney T, Molano RD, Pileggi A, Cattan P, Li H, et al. (2001) Patterns of engraftment in different strains of immunodeficient mice reconstituted with human peripheral blood lymphocytes. Transplantation 72: 133-140.
27. Marasco WA, (2005) Therapeutic antibody gene transfer. Nat Biotechnol 23: 551-552.
28. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, et al. (2005) Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 23: 584-590.
29. Li B, Zhang X, Shi S, Zhao L, Zhang D, et al. (2010) Construction and characterization of a bispecific anti-CD20 antibody with potent antitumor activity against B-cell lymphoma. Cancer Res 70: 6293-6302.
30. Gupta P, Han SY, Holgado-Madruga M, Mitra SS, Li G, et al. (2010) Development of an EGFRvIII specific recombinant antibody. BMC Biotechnol 10: 72.
31. Xu X, Clarke P, Szalai G, Shively JE, Williams LE, et al. (2000) Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 60: 4475-4484.
32. Repp R, Kellner C, Muskulus A, Staudinger M, Mohseni Nodehi S, et al. (2011) Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J Immunol Methods.
33. Presta LG, (2002) Engineering antibodies for therapy. Curr Pharm Biotechnol 3: 237-256.
34. Hadley AG, Zupanska B, Kumpel BM, Leader KA, (1992) The functional activity of Fc gamma RII and Fc gamma RIII on subsets of human lymphocytes. Immunology 76: 446-451.
35. Querfeld C, Mehta N, Rosen ST, Guitart J, Rademaker A, et al. (2009) Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma 50: 1969-1976.
36. Alinari L, Geskin L, Grady T, Baiocchi RA, Bechtel MA, et al. (2008) Subcutaneous alemtuzumab for Sezary Syndrome in the very elderly. Leuk Res 32: 1299-1303.
37. Ure UB, Ar MC, Salihoglu A, Guner SI, Baran A, et al. (2007) Alemtuzumab in Sezary syndrome: efficient but not innocent. Eur J Dermatol 17: 525-529.
38. Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, et al. (2007) Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 109: 4655-4662.
39. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, et al. (2006) Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 43: 16-24.
40. Beissert S, Schwarz A, Schwarz T, (2006) Regulatory T cells. J Invest Dermatol 126: 15-24.
41. Wang J, Ke XY, (2011) The four types of Tregs in malignant lymphomas. J Hematol Oncol 4: 50.
42. Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, et al. (2009) Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother 58: 1195-1206.
43. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, et al. (2010) Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28: 1591-1598.
44. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, et al. (2012) Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study. J Clin Oncol.
45. Wasik MA, Sioutos N, Tuttle M, Butmarc JR, Kaplan WD, et al. (1994) Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice. Am J Pathol 144: 1089-1097.
46. Luo Y, Dorf ME (2001) Isolation of mouse neutrophils. Curr Protoc Immunol Chapter 3: Unit 3 20.
47. Collaco RF, Cao X, Trempe JP, (1999) A helper virus-free packaging system for recombinant adeno-associated virus vectors. Gene 238: 397-405.
48. Michelfelder S, Lee MK, deLima-Hahn E, Wilmes T, Kaul F, et al. (2007) Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy. Exp Hematol 35: 1766-1776.
49. Veldwijk MR, Topaly J, Laufs S, Hengge UR, Wenz F, et al. (2002) Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol Ther 6: 272-278.
50. Loening AM, Gambhir SS, (2003) AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2: 131-137.